GlassScriptPhysician profile
Tracy A Carter
NPI 1962488130
$1,149.89
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $166 · 2021: $388 · 2022: $177 · 2023: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.38 | 2020-2023 | |
| Therapeuticsmd, INC. | $136.23 | 2020-2022 | |
| Pfizer INC. | $92.86 | 2021-2023 | |
| Astellas Pharma US INC | $82.60 | 2019-2023 | Myrbetriq, Veozah |
| Mylan Pharmaceuticals INC. | $80.57 | 2019-2021 | |
| Allergan, INC. | $68.74 | 2019-2020 | |
| Daiichi Sankyo INC. | $55.60 | 2019-2021 | |
| Novo Nordisk INC | $50.40 | 2023 | Ozempic, Rybelsus, Saxenda |
| Myovant Sciences INC. | $41.14 | 2021 | |
| Medtronic USA, INC. | $39.00 | 2019-2020 | |
| Agile Therapeutics, INC. | $32.07 | 2021-2023 | Twirla |
| Lupin INC. | $23.07 | 2019 | |
| Exeltis, USA INC. | $17.31 | 2021 | |
| Merck Sharp & Dohme LLC | $17.03 | 2021 | |
| Boston Scientific Corporation | $15.44 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $13.59 | 2021 | |
| Scynexis, INC. | $12.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.